

Date: 24 March 2025

To National Stock Exchange of India Limited Exchange Plaza, C-1, Block G, Bandra Kurla Complex, Bandra (E), Mumbai – 400 051 NSE Scrip Symbol: SaiLife	To BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street Mumbai – 400001 BSE Scrip Code: 544306
---	--

Sub: Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015.

Dear Sir/ Madam,

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform you that the Board of Directors of the Company, at its meeting held on Monday, 24 March 2025, inter-alia considered and approved the following:

1. Dr. Dinesh V Patel, (DIN:11010657) has been appointed as an Additional Director of the Company under the category of Independent Director for a first term of five consecutive years from 24 March 2025 to 23 March 2030 subject to approval of members in or before the ensuing Annual General Meeting (“AGM”).
2. Mr. Rajagopal Srirama Tatta, (DIN: 00988348) shall cease to be Independent Director of the Company w.e.f. closing of Business hours on 25 March 2025, consequent to the end of his term as an Independent Director.
3. Allotment of 12000 fully paid-up equity shares of Re.1/ each upon exercise of options granted under ESOP 2008.

The required disclosures to be made pursuant to the Regulation 30 read with Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 and SEBI Master Circular no. SEBI/HO/CFD/PoD2/CIR/0155 dated 11 November 2024 are enclosed herewith.

The Board Meeting was concluded at 06:24 PM (IST).

We request you to take note of the same and oblige.

Thank you.

For **Sai Life Sciences Limited**

Runa Karan
Company Secretary & Compliance Officer
Membership No.: A13721

Encl: As above

Sai Life Sciences Limited (CIN: U24110TG1999PLC030970)

Corporate office

L4-01 & 02, SLN Terminus, Survey
#133, Gachibowli Miyapur Road,
Gachibowli, Hyderabad – 500032,
Telangana, India.

Registered office

Plot No. DS-7, IKP Knowledge Park, Turkapally
(V), Shameerpet Mandal, Medchal-Malkajgiri
(Dist), Hyderabad -500078, Telangana, India.

Contact us

T: +91 40 6815 6000,
F: +91 40 6815 6199
E: info@sailife.com
W: www.sailife.com

ANNEXURE I

The details as required in terms of Regulation 30 read with of Schedule III of the LODR and SEBI Master Circular dated 11 November 2024 – Appointment of Dr. Dinesh V Patel, (DIN: 11010657)

S. No	Particulars	Description
1	Reason for change viz. appointment, re-appointment, resignation, removal, death or otherwise	Dr. Dinesh V Patel, (DIN: 11010657) has been appointed as an Additional Director of the Company under the category of Independent Director.
2	Date of appointment/re-appointment/cessation & term of appointment/re-appointment	Date of appointment is 24 March 2025. Terms of Appointment – First term of five consecutive years from 24 March 2025 to 23 March 2030 subject to approval of members in or before the ensuing AGM.
3	Brief Profile (In case of Appointment)	Dr. Patel has served as a member of the board of directors and as the President and Chief Executive Officer of Protagonist Therapeutics since December 2008. He has 38 years of executive, entrepreneurial, and scientific experience that span the pharmaceutical, biotechnology and biopharmaceutical industries. Prior to joining Protagonist, Dr. Patel served from 2006 to 2008 as the President and Chief Executive Officer of Arête Therapeutics, a privately held company focused on novel drugs for metabolic syndrome. Previously, he was the Chief Executive Officer and Co-founder of Miikana Therapeutics, an oncology based company, from 2003 until acquired by Entremed (later renamed CASI Pharmaceuticals) in 2005. Prior to Miikana, Dr. Patel held positions of increasing responsibility at Versicor (later renamed Vicuron) from 1996 to 2003, most recently as Senior Vice President of Drug Discovery and Licensing. Vicuron research and development efforts led to two marketed drugs, anidulafungin (Eraxis®), and Dalbavancin (Dalvance®), and the Company was acquired by Pfizer in 2005 in a \$1.9 billion cash transaction. From 1993 to 1996, Dr. Patel was a director of chemistry at the combinatorial chemistry company Affymax. Dr. Patel was a medicinal chemist at Bristol-Myers Squibb from 1985 to 1993. He received his Ph.D. in Chemistry from Rutgers University, New Jersey and his M.Sc. and B.Sc. in Chemistry from S. P. University, Vallabh Vidyanagar, India.
4	Disclosure of relationships between directors (in case of appointment of director)	Dr. Dinesh V Patel is not related to any of the Promoters, Directors or Key Managerial Personnel of the Company.
5	Information as required pursuant to BSE Circular no. LIST/COMP/14/2018-19 and NSE Circular No. NSE/CMU2018/24 dated 20 June 2018	Dr. Dinesh V Patel is not debarred from holding office of a director by virtue of any order passed by the Securities and Exchange Board of India or any other such authority.

Sai Life Sciences Limited (CIN: U24110TG1999PLC030970)

Corporate office

L4-01 & 02, SLN Terminus, Survey #133, Gachibowli Miyapur Road, Gachibowli, Hyderabad – 500032, Telangana, India.

Registered office

Plot No. DS-7, IKP Knowledge Park, Turkapally (V), Shameerpet Mandal, Medchal-Malkajgiri (Dist), Hyderabad -500078, Telangana, India.

Contact us

T: +91 40 6815 6000,
F: +91 40 6815 6199
E: info@sailife.com
W: www.sailife.com

ANNEXURE II

The details as required in terms of Regulation 30 read with of Schedule III of the LODR and SEBI Master Circular dated 11 November 2024 – Cessation of Mr. Rajagopal Srirama Tatta (DIN: 00988348) as an Independent Director of the Company.

S. No	Particulars	Description
1	Reason for change viz. appointment, re-appointment, resignation, removal, death or otherwise	The term of Mr. Rajagopal Srirama Tatta (DIN: 00988348) as an Independent Director of the Company, comes to an end at the closure of business hours on 25 March 2025 on completion of his tenure.
2	Date of appointment/re-appointment/cessation & term of appointment/re-appointment	At the closure of business hours on 25 March 2025
3	Brief Profile (In case of Appointment)	Not applicable
4	Disclosure of relationships between directors (in case of appointment of director)	Not applicable

Sai Life Sciences Limited (CIN: U24110TG1999PLC030970)

Corporate office

L4-01 & 02, SLN Terminus, Survey #133, Gachibowli Miyapur Road, Gachibowli, Hyderabad – 500032, Telangana, India.

Registered office

Plot No. DS-7, IKP Knowledge Park, Turkapally (V), Shameerpet Mandal, Medchal-Malkajgiri (Dist), Hyderabad -500078, Telangana, India.

Contact us

T: +91 40 6815 6000,
F: +91 40 6815 6199
E: info@sailife.com
W: www.sailife.com

Annexure III-A

Details under Regulation 10(c) of SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021.

1	Company name and address of Registered Office: Sai Life Sciences Limited Plot No. DS-7, IKP Knowledge Park, Turkapally (V) Shameerpet Mandal, Medchal-Malkajgiri Dist, Rangareddi, Hyderabad, Telangana, India, 500078
2	Name of the Stock Exchanges on which the company's shares are listed: BSE Limited ("BSE") National Stock Exchange of India Limited ("NSE")
3	Filing date of the statement referred in regulation 10(b) of the SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021 with Stock Exchange: 08 January 2025 (BSE & NSE)
4	Filing Number, if any: BSE: 220872 NSE: 46558
5	Title of the Scheme pursuant to which shares are issued, if any: Employees Stock Option Plan 2008
6	Kind of security to be listed: Equity Shares
7	Par value of the shares: Re 1/- per share
8	Date of issue of shares: 24 March 2025 (Allotment on exercise of options)
9	Number of shares issued: 12,000
10	Share Certificate No., if applicable: Not Applicable. Shares are issued in Dematerialized form
11	Distinctive number of the share, if applicable: 208099390 to 208402389 (both inclusive)
12	ISIN Number of the shares if issued in Demat: INE570L01029
13	Exercise price per share: Re 23.30/- per share for 7000 Equity Shares Re 188.90/- per share for 5000 Equity Shares
14	Premium per share: Re 22.30/- per share for 7000 Equity Shares Re 187.90/- per share for 5000 Equity Shares
15	Total Issued shares after this issue: 208402389
16	Total Issued share capital after this issue: 208402389
17	Details of any lock-in on the shares: NA
18	Date of expiry of lock-in: NA
19	Whether shares identical in all respects to existing shares if not, when will they become identical: NA
20	Details of listing fees, if payable: NA

Sai Life Sciences Limited (CIN: U24110TG1999PLC030970)

Corporate office

L4-01 & 02, SLN Terminus, Survey
#133, Gachibowli Miyapur Road,
Gachibowli, Hyderabad – 500032,
Telangana, India.

Registered office

Plot No. DS-7, IKP Knowledge Park, Turkapally
(V), Shameerpet Mandal, Medchal-Malkajgiri
(Dist), Hyderabad -500078, Telangana, India.

Contact us

T: +91 40 6815 6000,
F: +91 40 6815 6199
E: info@sailife.com
W: www.sailife.com

Annexure III-B

The details as required in terms of Regulation 30 read with of Schedule III of the LODR and SEBI Master Circular dated 11 November 2024

Sl. No.	Disclosures	Particulars – ESOP 2008
a)	brief details of options granted	The present instance is for allotment of shares upon exercise of 12000 options under ESOP 2008.
b)	Whether the scheme is in terms of SEBI (SBEB) Regulations, 2021 (if applicable)	Yes
c)	total number of shares covered by these options	The present disclosure is in respect of allotment of 12000 shares made on 24 th March, 2025.
d)	pricing formula	The price payable by an Employee on Exercise is determined by the Nomination and Remuneration Committee and in conformity with applicable accounting Standards, the SEBI SBEB & SE Regulations as applicable from time to time.
e)	options vested	NA as the intimation is towards allotment of shares pursuant to exercise of ESOPs
f)	time within which option may be exercised	NA as the intimation is towards allotment of shares pursuant to exercise of ESOPs
g)	options exercised	The present instance is for allotment of shares upon exercise of 12000 options under ESOP 2008.
h)	money realized by exercise of options	INR 11,07,600/-
i)	the total number of shares arising as a result of exercise of option	12000
j)	options lapsed	NA as the intimation is towards allotment of shares pursuant to exercise of ESOPs
k)	variation of terms of options	NA
l)	brief details of significant terms	The objective of ESOP 2008 is to provide an incentive to attract, retain and reward employees and contribute to the growth of the Company. The ESOP 2008 has a maximum vesting period of 5 years with multiple options of vesting as per clause 5 of the ESOP 2008. The exercise period is till the employee is in the service of the company as per clause 7 of ESOP 2008.
m)	subsequent changes or cancellation or exercise of such options	NA
n)	diluted earnings per share pursuant to issue of equity shares on exercise of options	NA

Sai Life Sciences Limited (CIN: U24110TG1999PLC030970)

Corporate office

L4-01 & 02, SLN Terminus, Survey #133, Gachibowli Miyapur Road, Gachibowli, Hyderabad – 500032, Telangana, India.

Registered office

Plot No. DS-7, IKP Knowledge Park, Turkapally (V), Shameerpet Mandal, Medchal-Malkajgiri (Dist), Hyderabad -500078, Telangana, India.

Contact us

T: +91 40 6815 6000,
F: +91 40 6815 6199
E: info@sailife.com
W: www.sailife.com